Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acadia Pharmaceuticals has received a grant of $300,000 from The Michael J Fox Foundation for the development of novel Nurr1-RXR agonists for the treatment of Parkinson's disease.
Subscribe to our email newsletter
The grant was awarded under the Foundation’s Therapeutics Development Initiative aimed at supporting preclinical development of Parkinson’s disease therapies that have the potential for fundamentally altering disease course and improving treatment of symptoms above and beyond current standards of care.
Acadia Pharma researchers will examine the effects of Nurr1-RXR agonists in preclinical models of Parkinson’s disease, focusing on neuroprotection, neuroregeneration, and motor performance.
Acadia Pharma CEO Uli Hacksell said that they are grateful for The Michael J Fox Foundation’s support of their Nurr1 program.
"We are committed to bringing forward therapies in this area of neurology and, in addition to preclinical programs addressing Nurr1 and ER-beta receptors for Parkinson’s disease, we are pursuing a Phase III program with pimavanserin for Parkinson’s disease psychosis," Hacksell said.